Puerto-Baracaldo Kathalina, Amaya-Montoya Mateo, Parra-Serrano Gustavo, Prada-Robles Diana C, Serrano-Gómez Sergio, Restrepo-Giraldo Lina M, Fragozo-Ramos María C, Tangarife Verónica, Giraldo-González Germán C, Builes-Barrera Carlos A, Naranjo-Vanegas Melisa S, Gómez-Aldana Andrés, Llano Juan Pablo, Gil-Ochoa Nayibe, Nieves-Barreto Luz D, Gaete Paula V, Pérez-Mayorga Maritza, Mendivil Carlos O
School of Medicine, Universidad de los Andes, Bogotá, Colombia (Drs Puerto-Baracaldo, Amaya-Montoya, Nieves-Barreto, Gaete and Mendivil).
Facultad de Salud, Universidad Autónoma de Bucaramanga, Bucaramanga, Colombia (Drs Parra-Serrano and Serrano-Gómez).
J Clin Lipidol. 2024 Nov-Dec;18(6):e1074-e1085. doi: 10.1016/j.jacl.2024.08.006. Epub 2024 Aug 19.
The genetic substrate of severe hypertriglyceridemia (sHTG) in Latin America is insufficiently understood.
To identify genetic variants in genes related to triglyceride (TG) metabolism among adults with sHTG from Colombia.
In individuals with plasma TG ≥ 880 mg/dL at least once in their lifetime, we amplified and sequenced all exons and intron/exon boundaries of the genes LPL, APOC2, APOA5, GPIHBP1 and LMF1. For each variant we ascertained its location, zygosity, allelic frequency and pathogenicity classification according to American College of Medical Genetics (ACMG) criteria.
The study included 166 participants (62% male, mean age 50 years), peak TG levels ranged between 894 and 11,000 mg/dL. We identified 92 variants: 19 in LPL, 7 in APOC2, 11 in GPIHBP1, 38 in LMF1, and 17 in APOA5. Eighteen of these variants had not been reported. We identified a new pathogenic variant in LMF1 (c.41C>A; p.Ser14*), a new likely pathogenic variant in LMF1 (c.1527 C > T; p.Pro509=, also expressed as c.1447C>T; p.Gln483*), and a known pathogenic variant in LMF1 (c.779G>A; p.Trp260*). Four participants were heterozygous for variant c.953A>G; p.Asn318Ser in LPL, a known risk factor for hypertriglyceridemia. Participants with variants of unknown significance (VUS) in LMF1 had significantly higher peak TG than those with VUS in other genes. Peak TG were 4317 mg/dL in participants with a history of pancreatitis, and 1769 mg/dL in those without it (p = 0.001).
Our study identified variants associated with sHTG among Latinos, and showed that genetic variation in LMF1 may be frequently associated with sHTG in this population.
拉丁美洲严重高甘油三酯血症(sHTG)的遗传基础尚未得到充分了解。
在哥伦比亚患有sHTG的成年人中鉴定与甘油三酯(TG)代谢相关基因的遗传变异。
对于一生中至少有一次血浆TG≥880mg/dL的个体,我们对LPL、APOC2、APOA5、GPIHBP1和LMF1基因的所有外显子以及内含子/外显子边界进行扩增和测序。对于每个变异,我们根据美国医学遗传学学会(ACMG)标准确定其位置、纯合度、等位基因频率和致病性分类。
该研究纳入了166名参与者(62%为男性,平均年龄50岁),TG峰值水平在894至11,000mg/dL之间。我们鉴定出92个变异:LPL基因中有19个,APOC2基因中有7个,GPIHBP1基因中有11个,LMF1基因中有38个,APOA5基因中有17个。其中18个变异尚未见报道。我们在LMF1基因中鉴定出一个新的致病性变异(c.41C>A;p.Ser14*),一个新的可能致病性变异(c.1527C>T;p.Pro509=,也表示为c.1447C>T;p.Gln483*),以及一个已知的LMF1基因致病性变异(c.779G>A;p.Trp260*)。4名参与者为LPL基因中c.953A>G;p.Asn318Ser变异的杂合子,该变异是高甘油三酯血症的已知危险因素。LMF1基因中具有意义未明变异(VUS)的参与者的TG峰值显著高于其他基因具有VUS的参与者。有胰腺炎病史的参与者TG峰值为4317mg/dL,无胰腺炎病史的参与者为1769mg/dL(p=0.001)。
我们的研究在拉丁裔人群中鉴定出了与sHTG相关的变异,并表明LMF1基因的遗传变异可能在该人群中与sHTG频繁相关。